Evidence map›Paper›PMID 40142637›Full record

ReviewJournal of clinical medicine2025

Functional Foods and Nutraceuticals in Irritable Bowel Syndrome.

Giovanni Marasco, Cesare Cremon, Daniele Salvi, David Meacci, Elton Dajti, Luigi Colecchia, Maria Raffaella Barbaro, Vincenzo Stanghellini, Giovanni Barbara

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. AGut microbiome (Cambridge, England) · 2026
    Article
  4. Diarrhea management: from pathophysiology to microbiota modulation.Therapeutic advances in gastroenterology · 2026
    Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Giovanni MarascoIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-7167-8773
Cesare CremonIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0002-7777-2936
Daniele SalviIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-7672-0686
David MeacciIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.
Elton DajtiIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.
Luigi ColecchiaIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0002-0217-8780
Maria Raffaella BarbaroIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.
Vincenzo StanghelliniDepartment of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.ORCID 0000-0003-0559-4875
Giovanni BarbaraIRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction, with a multifactorial pathophysiology involving gut-brain axis dysregulation, visceral hypersensitivity, microbiota imbalance, and immune dysfunction. Traditional IBS management emphasizes dietary modifications and pharmacologic therapies. However, increasing attention has been directed toward functional foods, nutraceuticals, and herbal remedies due to their potential to target IBS pathophysiological mechanisms with favorable safety profiles. This clinical review explores the role of these adjunctive therapies, evaluating evidence from preclinical and clinical studies. Functional foods such as kiwifruit, prunes, and rye bread demonstrate benefits in bowel habit regulation through fiber content and microbiota modulation. Nutraceuticals like peppermint oil, palmitoylethanolamide, and herbal mixtures exhibit anti-inflammatory, antispasmodic, and analgesic effects. Prebiotics provide substrate-driven microbiota changes, although dosage is key, as given their fermentative properties, when used at high dosages, they can exacerbate symptoms in some individuals. Probiotics and postbiotics offer microbiota-based interventions with promising symptom relief in IBS subtypes, although factors for personalized treatment still need to be further elucidated. These strategies highlight a paradigm shift in IBS management, integrating diet-based therapies with evolving nutraceutical options to improve patient outcomes. Despite promising findings, challenges in standardizing definitions, mechanisms, and safety profiles still remain. Rigorous, large-scale trials to validate the therapeutic potential of these interventions are needed, to enhance the benefits of these compounds with an individualized treatment approach.

Indexed as

disorders of gut–brain interactionessential oilsirritable bowel syndromeprobiotics

Identifiers

PMID40142637
PMCPMC11943262

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.